Will ETA-antibody arouse new interest in cancer therapeutics?

Ji-Young Park; Chang-Han Lee

doi:10.1016/j.tips.2021.11.013

Will ET_A-antibody arouse new interest in cancer therapeutics?

Trends Pharmacol Sci. 2022 May;43(5):352-354. doi: 10.1016/j.tips.2021.11.013. Epub 2021 Dec 9.

Authors

Ji-Young Park¹, Chang-Han Lee²

Affiliations

¹ Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
² Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Republic of Korea; Department of Pharmacology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea; BK21 FOUR Biomedical Science Project, Seoul National University College of Medicine, Seoul 03080, Republic of Korea; SNU Dementia Research Center, Seoul National University College of Medicine, Seoul 03080, Republic of Korea; Wide River Institute of Immunology, Seoul National University, Hongcheon 25159, Republic of Korea. Electronic address: chlee-antibody@snu.ac.kr.

PMID: 34895946
DOI: 10.1016/j.tips.2021.11.013

Abstract

Although endothelin receptor type A (ET_A) is emerging as a novel anticancer target, previously only small molecule drugs have been available as ET_A antagonists. Ju and colleagues have successfully developed a functional anti-ET_A antibody for colorectal cancer.

Keywords: ET(A) antagonist; GPCR; cancer stem cell; therapeutic antibody.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies / therapeutic use
Endothelins*
Humans
Neoplasms* / drug therapy
Receptor, Endothelin A

Substances

Antibodies
Endothelins
Receptor, Endothelin A